Clinical Trial Update: Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the addition of raltegravir to protease inhibitor- or NNRTI-based ART in HIV-infected individuals with undetectable viral load.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Not specified
• Raltegravir (raltegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2011-06-23